Reported September 8, 2026: 'Tylenol Use In Pregnancy May Be Linked With Uterus, Ovary Changes In Daughters' - Reuters News

Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $287 Price Target

Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $287 price target.

Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?

Johnson & Johnson is expected to report Q3 2026 earnings of $2.90 per share (up 3.6% YoY) and revenues of $25.37 billion (up 5.8% YoY) on October 13. However, the company's Earnings ESP is -0.01% with a Zacks Rank #3, making it difficult to predict an earnings beat. While JNJ has beaten consensus estimates in all four of the last quarters, recent analyst revisions have turned slightly bearish, suggesting the stock may not be a compelling earnings-beat candidate.

9 Of 11 Sectors Rise In Tuesday Trading As Defensives Lead

Nine of 11 sectors are higher in Tuesday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Utilities well ahead of the next group.

RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $290

Kimberly-Clark May Sell Assets to Save Its $40 Billion Kenvue Deal: Report

Kimberly-Clark prepares EU concessions to win approval for its $40B Kenvue deal, following Australian divestiture demands.

Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

Kenvue (KVUE) is highlighted as a smart high-yield dividend stock with a 4.68% dividend yield and 64 consecutive years of dividend increases, making it a Dividend King. The company, spun off from Johnson & Johnson three years ago, generates steady revenue from recession-resilient consumer healthcare brands like Tylenol and Neutrogena. However, uncertainty exists due to a pending acquisition by Kimberly-Clark (KMB), another Dividend King with a 5.23% yield.